2020—2022年某院住院患者口服降糖药物使用情况分析

Analysis on the Use of Oral Hypoglycemic Drugs at the Inpatient from 2020 to 2022

目的:统计分析某院住院患者口服降糖药的使用情况,为口服降糖药的合理使用提供参考。方法:统计2020—2022年某院住院患者口服降糖药的应用数据,获取该类药年销售总金额和年出库总量等相关信息,采用世界卫生组织推荐的限定日剂量(DDD)分析法,回顾性分析住院口服降糖药的销售金额、用药频度(DDDs)、限定日费用(DDC)及排序比(B/A)等指标。结果:某院2020—2022年各类口服降糖药的销售总金额呈每年递增趋势,其中二肽基肽酶(DPP-4)抑制剂的销售金额连续3年位列首位;2021—2022年二甲双胍和达格列净的DDD位列前2位;吡格列酮DDC连续3年列首位,其中二甲双胍DDC下降最为明显;二甲双胍B/A最大,利格列汀B/A最小。结论:2020—2022年某院住院口服降糖药的临床选用基本合理,符合指南推荐。

Objective:Statistics and analysis have been made on the use of oral hypoglycemic drugs at the inpatient of a hospital from 2020 to 2022,so as to provide reference for the rational use of oral hypoglycemic drugs.Methods:The application data of inpatients with oral hypoglycemic drugs in a hospital from 2020 to 2022 were collected to obtain the annual total amount of sales and the annual total amount of delivery,etc.The defined daily dose(DDD)analysis method recommended by the World Health Organization was adopted.The consumption sum,defined daily dose system(DDDs),defined daily cost(DDC)and sequence number ratio(B/A)of oral hypoglycemic drugs in a hospital were analyzed retrospectively.Results:From 2020 to 2022,the total consumption sum of various oral hypoglycemic drugs in a hospital increased annually,and the consumption sum of dipeptidyl peptidase(DPP-4)inhibitors ranked first for three consecutive years.The DDDs of metformin and dagliazine occupied the first two in the second two years;Pioglitazone DDC ranked first for 3 consecutive years,and metformin DDC decreased most obviously.The maximum B/A was found in metformin and the minimum in Linagliptin.Conclusion:The clinical selection of oral hypoglycemic drugs in a hospital from 2020 to 2022 is basically reasonable and in line with the recommendations of the guidelines.